Phase I trial of RGB 286638 in patients with solid tumours.
Latest Information Update: 28 Oct 2015
At a glance
- Drugs RGB 286638 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 09 Dec 2008 Status changed from planning to recruiting according to a GPC Biotech media release.
- 28 Feb 2008 This trial is expected to begin within the next 6 months.
- 28 Feb 2008 New trial record.